This observational, multicenter survey is designed to assess the efficacy of oral ibandronate in adults with breast cancer and metastatic bone disease. Data on the use of ibandronate in clinical practice will be collected from Hungarian patients.

Inclusion Criteria:

• Adults at least 18 years of age
• Histologically confirmed breast cancer with bone metastasis
• Receiving or indicated for the tablet formulation of ibandronate according to the summary of product characteristics (SmPC) and local labeling

Exclusion Criteria:

• Contraindication to ibandronate according to SmPC
• Ongoing participation in any trial evaluating the efficacy and/or safety of ibandronate

Breast cancer patients with metastatic bone disease who are receiving oral ibandronate will be followed for approximately 1 year.